Pulmonary tuberculosis

This study tests whether tuberculosis (TB) treatment can be tailored to each person's risk of a poor outcome. About 900 adults with drug-sensitive TB will be grouped as lower-risk or higher-risk. Lower-risk participants may get a shorter treatment course, while higher-risk partic…

This study tests an experimental vaccine called ID93 + GLA-SE in 1500 people with drug-susceptible pulmonary TB. Participants receive the vaccine or a placebo alongside their regular TB treatment. Researchers want to see if the vaccine can improve immune responses and reduce poor…

This phase 2 trial is testing whether new combinations of anti-tuberculosis drugs, including the experimental drug TBAJ-587, can effectively treat newly diagnosed, drug-sensitive pulmonary tuberculosis. The study involves 135 adults and compares several experimental regimens agai…

Many people who recover from tuberculosis are left with long-term lung damage, known as post-tuberculosis lung disease (PTLD), which can cause breathing problems and reduce quality of life. This study follows 760 participants—including people with active TB, those with establishe…

This study tests whether structured psychosocial counseling can improve treatment adherence in adults newly diagnosed with pulmonary tuberculosis. Participants in 10 primary health centers in Indonesia will either receive standard care or standard care plus counseling sessions. T…

This study looks at whether shorter, rifapentine-based treatments for tuberculosis and latent TB are safe and effective in real-world settings in Kazakhstan. It will follow 350 adults, including those with HIV, comparing a 4-month regimen to the standard 6-month one for active TB…

This study tests whether a shorter, 5-month combination of TB drugs works as well as the standard 6-month treatment for people with both HIV and drug-susceptible tuberculosis. It involves 148 participants with very weak immune systems (CD4 count under 100). The goal is to see if …

This Phase II trial tests whether an AI-optimized combination of pyrazinamide and hydroxychloroquine works better than the standard four-drug RIPE regimen for newly diagnosed drug-sensitive pulmonary tuberculosis. Two hundred adults will receive either the new AI-personalized tre…

This phase 3 trial tests a 9-month, all-oral combination of four drugs (BLMZ) for people aged 12 and older with rifampicin-resistant tuberculosis. The goal is to see if this shorter regimen leads to a cure without the need for injections. Participants take the pills daily or week…

This study looks at people who have TB-like changes on chest X-rays but negative sputum tests. It compares different treatment lengths (8 to 24 weeks) versus close monitoring without immediate treatment. The goal is to find the shortest effective treatment and understand who real…

This study tests whether an AI-powered digital stethoscope can help health workers more accurately diagnose pneumonia in children aged 2 months to 5 years. 350 children with cough or breathing difficulty will be randomly assigned to standard care or care plus the AI stethoscope. …

This study tests a new blood test that looks for TB DNA in the blood. It aims to see if it works as well as a bronchoscopy (a scope down the throat) to diagnose lung tuberculosis. 600 adults who need a bronchoscopy will give a blood sample for comparison. If successful, patients …

This study aims to better understand tuberculosis (TB) across its entire spectrum—from early, symptom-free infection to active disease and after treatment. Researchers will recruit TB patients and their close contacts to analyze immune responses and identify biomarkers that could…

This trial evaluates an active case-finding strategy to detect pulmonary tuberculosis (TB) among people with chronic obstructive pulmonary disease (COPD) in primary care clinics in Henan, China. The strategy uses computer-aided diagnosis and a rapid TB test during routine COPD vi…

This study will use artificial intelligence to analyze data from over 31,000 tuberculosis patients. The goal is to create a system that helps doctors decide which patients can be cured with a short treatment course and which need longer therapy. The AI will be tested to see if it…

This study looks at how people diagnosed with tuberculosis (TB) in rural and coastal areas of Southwest England experience stigma. Researchers will interview 20 patients to understand how stigma affects their lives and access to care. The goal is to develop better ways to support…

This study will test 250 people with tuberculosis (TB) to see how common drug resistance is. Using special rapid tests called GeneXpert, researchers will look for resistance to key TB drugs like Rifampicin. They also want to find out if things like diabetes or drug addiction make…

This study in Kenya will test whether a new blood test, called PATHFAST TB LAM ag, can better track how well tuberculosis (TB) treatment is working. Researchers will follow 300 adults with TB, collecting samples regularly during their 6-month treatment. The goal is to see if chan…